Michael Thomas

Research interests

Publications

• Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.08.002

• Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00247-3

• Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2002787

• A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

  Cancer Immunology Immunotherapy · 2019 · https://doi.org/10.1007/s00262-019-02315-x

• Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians

  Translational Lung Cancer Research · 2018 · https://doi.org/10.21037/tlcr.2018.08.14

• Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

  The Lancet Respiratory Medicine · 2017 · https://doi.org/10.1016/s2213-2600(17)30129-7

• Early palliative care for adults with advanced cancer

  Cochrane Database of Systematic Reviews · 2017 · https://doi.org/10.1002/14651858.cd011129.pub2

• Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00614-2

• Non‐small cell lung cancer is characterized by dramatic changes in phospholipid profiles

  International Journal of Cancer · 2015 · https://doi.org/10.1002/ijc.29517

• When do we need to care about the caregiver? Supportive care needs, anxiety, and depression among informal caregivers of patients with cancer and cancer survivors

  Cancer · 2015 · https://doi.org/10.1002/cncr.29223

• Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1311107

• Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(14)60845-x

• PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.47.1102

• Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1214886

• The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.37.2185

• Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.39.2993

• Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70063-3

• Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.28.5981

• Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

  Journal of Thoracic Oncology · 2010 · https://doi.org/10.1097/jto.0b013e3181f1c8de

• Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.1321

• Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer

  The Lancet Oncology · 2008 · https://doi.org/10.1016/s1470-2045(08)70156-6

• S100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer

  Cancer Research · 2004 · https://doi.org/10.1158/0008-5472.can-04-2004

• MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer

  Oncogene · 2003 · https://doi.org/10.1038/sj.onc.1206928

• Screening for Early Lung Cancer with Low-Dose Spiral CT: Prevalence in 817 Asymptomatic Smokers

  Radiology · 2002 · https://doi.org/10.1148/radiol.2223010490

• Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.

  Journal of Clinical Oncology · 1998 · https://doi.org/10.1200/jco.1998.16.6.2164

Current projects

No projects listed.